Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Glenmark Life Sciences Limited ( (IN:ALIVUS) ) has issued an update.
Alivus Life Sciences has clarified the operational impact of a February 14 fire at its Dahej manufacturing facility in Gujarat, confirming that the incident was confined to one of seven production blocks and affected only a portion of its intermediate manufacturing capacity. The API manufacturing facilities within the same block, along with the other six production blocks at the site, remain unaffected and fully operational.
Following a full assessment of the situation, the company expects to resume API production in the affected block from March 1, 2026, and restart intermediate production by mid-March 2026, with the temporary shutdown leading to some delayed shipments. Alivus emphasized that safety remains a paramount priority and said it continues to follow stringent safety protocols across its operations, seeking to reassure stakeholders about business continuity and risk management at the site.
More about Glenmark Life Sciences Limited
Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, operates in the pharmaceuticals sector with a focus on manufacturing Active Pharmaceutical Ingredients (APIs) and intermediates. The company runs multiple production blocks at its Dahej facility in Gujarat, underscoring its role as a key API and intermediate supplier to regulated markets.
Average Trading Volume: 38,786
Technical Sentiment Signal: Sell
Current Market Cap: 108.6B INR
For an in-depth examination of ALIVUS stock, go to TipRanks’ Overview page.